MoonLake Immunotherapeutics (MLTX) Change in Accured Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 557.78% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $11.3 million (up 75.55% YoY), while the FY2025 annual figure was $2.6 million, down 49.87% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $7.1 million, up from -$6.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $12.9 million in Q3 2025, with the low at -$6.9 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $1.4 million (2023), against an average of $1.0 million.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses slumped 18799.85% in 2022, then jumped 557.78% in 2026.
• MoonLake Immunotherapeutics' Change in Accured Expenses stood at $2.2 million in 2022, then climbed by 28.06% to $2.9 million in 2023, then surged by 45.51% to $4.2 million in 2024, then sank by 265.24% to -$6.9 million in 2025, then surged by 203.28% to $7.1 million in 2026.
• Business Quant data shows MLTX's Change in Accured Expenses at $7.1 million in Q1 2026, -$6.9 million in Q4 2025, and $12.9 million in Q3 2025.